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Abstract
Introduction: Nonalcoholic fatty liver disease (NAFLD) can be seen as a manifestation of overnutrition. The muscle is a
central player in the adaptation to energy overload, and there is an association between fatty-muscle and -liver. We aimed
to correlate muscle morphology, mitochondrial function and insulin signaling with NAFLD severity in morbid obese
patients.
Methods: Liver and deltoid muscle biopsies were collected during bariatric surgery in NAFLD patients. NAFLD Activity Score
and Younossi’s classification for nonalcoholic steatohepatitis (NASH) were applied to liver histology. Muscle evaluation
included morphology studies, respiratory chain complex I to IV enzyme assays, and analysis of the insulin signaling cascade.
A healthy lean control group was included for muscle morphology and mitochondrial function analyses.
Results: Fifty one NAFLD patients were included of whom 43% had NASH. Intramyocellular lipids (IMCL) were associated
with the presence of NASH (OR 12.5, p,0.001), progressive hepatic inflammation (p=0.029) and fibrosis severity (p=0.010).
There was a trend to an association between IMCL and decreased Akt phosphorylation (p=0.059), despite no association
with insulin resistance. In turn, hepatic steatosis (p=0.015) and inflammation (p=0.013) were associated with decreased Akt
phosphoryation. Citrate synthase activity was lower in obese patients (p=0.047) whereas complex I (p=0.040) and III
(p=0.036) activities were higher, compared with controls. Finally, in obese patients, complex I activity increased with
progressive steatosis (p=0.049) and with a trend with fibrosis severity (p=0.056).
Conclusions: In morbid obese patients, presence of IMCL associates with NASH and advanced fibrosis. Muscle mitochondrial
dysfunction does not appear to be a major driving force contributing to muscle fat accumulation, insulin resistance or liver
disease. Importantly, insulin resistance in muscle might occur at a late point in the insulin signaling cascade and be
associated with IMCL and NAFLD severity.
Citation: Machado MV, Ferreira DMS, Castro RE, Silvestre AR, Evangelista T, et al. (2012) Liver and Muscle in Morbid Obesity: The Interplay of Fatty Liver and
Insulin Resistance. PLoS ONE 7(2): e31738. doi:10.1371/journal.pone.0031738
Editor: Lise Lotte Gluud, Copenhagen University Hospital Gentofte, Denmark
Received October 14, 2011; Accepted January 12, 2012; Published February 16, 2012
Copyright:  2012 Machado et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant: PTDC/SAU-OSM/100878/2008, from FCT, Portugal. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hlcortezpinto@netcabo.pt
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a condition
characterized by fat accumulation in the liver, not related with
alcohol consumption. It represents a wide spectrum of pathological
subgroups, from benign simple steatosis to nonalcoholic steatohepa-
titis (NASH), which can progress to hepatic cirrhosis [1], and is
associated with overalland liver-relatedincreased mortality[2].Two
of the main risk factors for developing NAFLD are insulin resistance
and obesity, in which the peripheral adipose tissue reservoir capacity
is overwhelmed, allowing ectopic fat accumulation.
There is increasing awareness of the importance of the muscle
as a central player in the adaptation to an excessive input of
energy, as one of the main fuel consuming organs [3]. In the
muscle, lipids are stored either as metabolically inert interstitial
adipocyte triglycerides in the interfascicular space, extramyocel-
lular lipids (EMCL), or droplets in the cytoplasm of myocytes,
intramyocellular lipids (IMCL) [4]. IMCL accumulate in athletes,
where they are in constant turnover and believed to act as fuel [5],
or in association with obesity, insulin resistance/type 2 diabetes
mellitus and high fat diets [6,7,8,9]. In this case, lipids are either
not consumed or incompletely oxidized, potentially forming
dangerous active metabolites that may inhibit the insulin signaling
cascade [10,11,12,13,14], thus further contributing to metabolic
disturbances. In fact, IMCL may constitute the missing link
between obesity and development of insulin resistance, since
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exercise training, even in the absence of significant changes in total
body adiposity [15]. In addition, interventions in obese individuals
that decrease IMCL result in better glucose control [16].
Nonetheless, the accumulation of active fatty acids metabolites
such as acyl CoA, ceramides and diacylglycerol, rather than the
accumulation of triglycerides, may play a major role in insulin
signaling impairment. In fact, the up-regulation of triglyceride
synthesis was able to protect skeletal muscle from fat-induced
insulin resistance in a mouse model [17].
Previous studies with indirect assessment of ectopic fat in the
liver and muscle, either by computer tomography scan [18] or
magnetic resonance spectroscopy [7], have suggested that fat
accumulation in these two tissues may be correlated. Therefore,
we aimed to evaluate skeletal muscle changes in morphology,
mitochondrial function and insulin signaling, in morbidly obese
patients, and correlate them with NAFLD severity.
Methods
Patients
A cross-sectional study was performed with prospective and
consecutive recruitment of morbid obese patients submitted to
bariatric surgery, at Hospital of Santa Maria, CHLN, Lisbon,
Portugal, from 2006 to 2009. Inclusion criteria were age higher or
equal to 18 years old and indication to bariatric surgery. This was
defined as body mass index (BMI) superior or equal to 40 kg/m
2 or
superior to 35 kg/m
2 if associated with significant morbidity related
with obesity [19], such as arterial hypertension, diabetes mellitus
type 2, obstructive sleep apnea or dyslipidemia. Exclusion criteria
were: significant alcohol consumption defined as superior to 20
grams per day; positivity to hepatitis B virus surface antigen;
positivitytoanti-hepatitisC virus; othertypeofliver diseasesnamely
primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing
cholangitis, Wilson’s disease, hemochromatosis or a1-antitripsin
deficiency; treatment with potentially steatogenic drugs such as
steroids, high-dose estrogen, tamoxifen, methotrexate or amioda-
rone within six months of enrollment and history of gastrointestinal
bypass surgery or segmental small bowel resection. The study
protocol conformed to the Ethical Guidelines of the 1975
Declaration of Helsinki, revised in 2000, as reflected in an a priori
approval by the Hospitalde Santa MariaHumanEthics Committee
and written informed consent was obtained from all participants.
Clinical assessment and laboratorial tests
Patients were submitted to an interview assessing past medical
history and a semi-structured questionnaire regarding alcohol
consumption. BMI was defined as an individual’s weight in
kilograms divided by the square of height in meters (kg/m
2). Waist
was measured at half way between the inferior rib and the iliac
crest and hip was measured at the gluteus muscle at the level of
maximum circumference. Hypertension was defined as a systolic
blood pressure greater than or equal to 140 mmHg, a diastolic
blood pressure greater than or equal to 90 mmHg or as being
treated with antihypertensive drugs [20].
Venous blood was drawn in the morning after an overnight fast.
Laboratorial assessment included liver biochemistry, plasma
concentrations of cholesterol, high-density lipoprotein-cholesterol
(HDL-C), triglycerides, insulin and glucose. LDL-cholesterol was
calculated by the Friedewald’s equation i.e. [total cholesterol –
HDL-cholesterol – (triglycerides/5)]. Homeostasis model assess-
ment of insulin resistance (HOMA-IR) was calculated using fasting
glucose and insulin measurements: (fasting insulin (mU/mL)6fast-
ing glucose (mmol/L)/22.5) [21]. Insulin resistance was considered
if HOMA was greater than or equal to 3 [22]. Diabetes mellitus
was defined as fasting blood glucose greater than or equal to
126 mg/dL (7 mmol/L), or by the regular use of hypoglycemic
medications [23]. Metabolic syndrome was defined according to
the Third Adult Treatment Panel of the National Cholesterol
Education Program, as the presence of at least three of the
following criteria: central obesity (waist circumference greater than
102 cm in men and 88 cm in women), hypertriglyceridemia
(greater than or equal to 150 mg/dL), low HDL-cholesterol (lower
than 40 mg/dL in men and 50 mg/dL in women), elevated fasting
glucose (higher than 110 mg/dL) or the use of hipoglicemic drugs
and high blood pressure (higher or equal to 130/85 mmHg or
under antihypertensive drugs) [24].
Serum levels of adiponectin, leptin and ghrelin were assessed by
enzyme-linked immunosorbent assay (ELISA) or radioimmunoas-
say (RIA). In order to minimize individual variations, serum levels
were determined in duplicate.
Liver Biopsies
At the time of surgery, all patients were submitted to wedge liver
biopsy. All biopsies were evaluated by the same experienced
hepatopathologist, blinded to the laboratorial parameters and
clinical data. The specimens were fixed in formalin, embedded in
paraffin and stained with hematoxylin eosin, Masson trichrome and
reticulin coloration. NAFLD was defined as the presence of more
than 5% of steatosis in the liver [25] and NASH was defined as any
degree of steatosis along with centrilobular ballooning and/or
Mallory-Denk bodies or any degree of steatosis along with
centrilobular pericellular/perisinusoidal fibrosis or bridging fibrosis
in the absence of another identifiable cause [26]. Steatosis severity
was graded from 0 to 3 according to steatosis in less than 5% of
hepatocytes, 5–33%, 33–66% and more than 66%; hepatocyte
ballooning was classified from 0 to 2, namely absent, few or many;
lobular inflammation was classified from 0 to 3, according to the
presence of no inflammatory foci, mild or less than 2 foci per 2006
field,moderate or 2–4 foci per2006field and severeor more than 4
foci per2006foci.Finally, fibrosiswasstagedfrom 0 to4,according
to no fibrosis, perisinuoidal or periportal, perisinusoidal and
periportal, bridging fibrosis or cirrhosis, as described by the
Pathology Committee of NASH Clinical Research Network [27].
Deltoid Muscle Biopsies
Deltoid muscle samples from 51 morbidly obese patients with
NAFLD and 34 lean healthy controls were evaluated. Left deltoid
muscle biopsies were obtained during surgery, with collection of
three fragments, of about 1065 mm in size, which were
immediately flash frozen in 2-methylbutan cooled in liquid
nitrogen and kept at 280uC. Two fragments were used for
histological evaluation and biochemistry.
Histological evaluation of muscle biopsies included myocyte
fibers morphology, lipid and glycogen content, inflammation and
necrosis, as well as mitochondrial abnormalities. Morphological
characterization of muscle fibers was performed using the ATPase
technique, with pre-incubation at pH 9.4 that allows differentia-
tion according to the intensity of the stain; light fibers were
classified as type I and dark fibers as type II. To evaluate the
proportion of each type of fiber, computerized counting of 400
consecutive muscle fibers was performed using informatics
program Motic Images Advanced 3.1. In addition, the lower
diameter of 150 consecutive muscle fibers was measured to
evaluate length variation. Semi-quantitative assessment of lipid
content was performed with the Oil Red stain, to differentiate
intramyocellular and/or extramyocellular and interfascicular
lipids overload. Glycogen content was assessed with the Period-
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abnormalities included the determination of ragged red fibers
(RRF) with modified Gomori Trichrome stain, which allows the
identification of a peripheral reddish discoloration translating
excessive mitochondrial proliferation; and cytochrome c oxidase
(COX) negative fibers, through histoenzymatic evaluation with the
identification of fibers with no COX activity as a result of
mitochondrial DNA mutations that predominantly compromise
complex IV of the mitochondrial respiratory chain.
The mitochondrial respiratory chain enzymes activities were
evaluated with an enzymatic assay through spectrophotometric
analysis to determine complex I (NADH-ubiquinone oxidoreduc-
tase), II (succinate-ubiquinone reductase), III (ubiquinol-cyto-
chrome c reductase) and IV (cytochrome c oxidase), as well as
citrate synthase, activities. Each complex enzymatic assay was
normalizated with the citrate synthase activity of each sample.
Assays were performed using cellular homogenates of 50–80 mg of
muscle. Three assays for each enzyme in each sample were done
using a spectrophotometer Shimadzu CPS-240A and the infor-
matics program PC160PLS.
Muscle Insulin Signaling Cascade
Muscle samples from 26 patients were used to evaluate insulin
signaling cascade through immunoblotting. Total protein extracts
were subjected to SDS-PAGE electrophoresis [28]. Blots were
incubated with primary rabbit polyclonal antibodies against insulin
receptor, phosphorylated insulin receptor Tyr1162/1163, insulin
receptor substrate-1 (IRS-1), phosphorylated IRS-1 Tyr632, or with
primary mouse monoclonal antibodies reactive to Akt and
phosphorylated Akt Ser473 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and finally with secondary antibodies conjugated
with horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA,
USA). Levels of phosphorylated proteins were normalized to
corresponding unphosphorylated proteins. Glyceraldehyde-3-phos-
phate dehydrogenase was used as loading control. Membranes were
processed for protein detection using Super Signal substrate (Pierce,
Rockford, IL, USA). The relative intensities of protein bands were
analyzed using a densitometry analysis program (Quantity One
Version 4.6; Bio-Rad Laboratories).
Statistical Analysis
Basic descriptive statistics means, standard deviation, ranges
and percentages, were used to characterize the different
populations. Qualitative variables were analyzed by x
2 test and
one-way ANOVA. Results are also presented as odds ratio (OR)
with 95% confidence interval (CI). Quantitative variables were
compared by unpaired Student’s t-test and one-way ANOVA and
correlations by Pearson correlation coefficient. The independence
of the associations of variables with the presence of NASH
(dependable variable) was assessed by multivariable logistic
regression analysis and expressed as odds ratio (OR). The
covariates included were selected by their statistical association
in univariate analysis. Analyzes were run using SPSS software
version 16.0 (SPSS, Chicago, IL) for Windows and GraphPad
InStat version 3.00 (GraphPad Software, San Diego, CA, USA)
for the analysis of variance and Bonferroni’s multiple comparison
tests. Two-tailed P values less than 0.05 were considered
statistically significant.
Results
Patients’ characteristics
Fifty one morbid obese patients with NAFLD were included, of
whom 22 (43%) were classified as NASH (Typical case - Figure 1
B) and 29 (57%) as non-NASH (Typical case - Figure 1 A). One
patient (4%) had unsuspected hepatic cirrhosis. Thirteen patients
were male and mean body mass index was 4566 kg/m
2. Insulin
resistance was present in 57%, diabetes mellitus 26%, arterial
hypertension 39% and metabolic syndrome 43%. Main charac-
teristics of the patient population are showed in Table 1.
Metabolic factors and hepatic histology
Age, male:female ratio and anthropometric parameters includ-
ing BMI were similar in NASH and non-NASH patients. NASH
was associated with the presence of insulin resistance (OR 4.76
[1.23–18.52], p=0.045) and metabolic syndrome (OR 3.41 [1.15–
11.22], p=0.038), as well as higher levels of gamma-glutamyl
transpeptidase (c-GT) (Table 1). In multivariate analysis, the
metabolic syndrome lost statistical significance. Plasma levels of
adipokines (adiponectin, leptin) and ghrelin were not associated
with NASH.
Steatosis severity paralleled a progressive increase in insulin
levels (p=0.002), mean HOMA-IR (p=0.001) and prevalence of
insulin resistance (p=0.009) (Figure 2 A). Also, steatosis severity
was associated with progressively higher levels of aminotransfer-
ases serum levels, aspartate – AST (p=0.011) and alanine
aminotransferase – ALT (p=0.001). Similarly, there was a
statistical positive association between fibrosis stage and higher
levels of c-GT (p=0.003), insulin (p=0.006) (Figure 2) and
HOMA-IR (p=0.005) (Figure 2B), as well as progressively higher
Figure 1. Liver histology. Slides stained with hematoxylin & eosin representing patients with simple steatosis (206) (A) and NASH (406) (B). Note
the presence of a ballooned hepatocyte and lobular inflammatory infiltrate. Insert: ballooned hepatocyte with a Mallory-Denk body and
megamitochondria.
doi:10.1371/journal.pone.0031738.g001
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syndrome (p=0.029). There was also a trend to a positive
association between age and fibrosis severity (p=0.054). Lastly,
progressive lobular inflammatory activity was not associated with
HOMA-IR (p=0.065) (Figure 2C) or insulin resistance
(p=0.120), but was associated with older age (p=0.001), AST
(p,0.001) and ALT serum levels (p,0.001), as well as higher
prevalence of the metabolic syndrome (p=0.031).
Table 1. Patients main features.
Characteristic Total (N=51) NASH (N=22) No NASH (N=29) P* OR [95%CI]
Age (years) 42610 45694 1 611 0.105
Male sex (%) 26 32 21 0.280 0.56 [0.16–2.00]
BMI (kg/m
2)4 5 664 5 664 6 67 0.739
Waist (cm) 132613 133617 134617 0.930
WTH ratio 0.9760.10 1.0160.10 0.9660.11 0.095
Diabetes mellitus (%) 26 27 24 0.525 1.18 [0.33–4.18]
Insulin resistance (%) 57 79 44 0.020 4.77 [1.23–18.53]
HOMA 3.962.3 4.762.4 3.362.0 0.049
Hypertension (%) 39 41 38 0.528 1.13 [0.36–3.52]
Smoking (%) 30 24 34 0.311 0.59 [0.17–2.10]
Sleep apnea (%) 23 23 24 0.588 0.92 [0.25–3.43]
Hypertrigliceridaemia (%) 19 25 15 0.305 1.92 [0.44–8.41]
Triglycerides (mg/dL) 119643 127649 112637 0.223
HDL-cholesterol (mg/dL) 51613 48612 53613 0.146
LDL-cholesterol (mg/dL) 122636 128630 117640 0.293
Metabolic syndrome (%) 43 59 30 0.037 3.43 [1.15–11.22]
AST (IU/L) 27620 31629 2469 0.272
ALT (IU/L) 33629 41642 27612 0.141
c-GT (IU/L) 37645 54664 25614 0.022
ALP (IU/L) 74622 73626 71614 0.306
Total bilirubin (mg/dL) 0.760.4 0.660.2 0.760.4 0.274
Adiponectin (ng/mL) 20.766.2 21.167.7 20.465.3 0.798
Leptin (ng/mL) 19.867.3 19.967.3 19.767.5 0.912
Ghrelin (pg/mL) 20.8613.1 18.8613.9 21.9612.8 0.481
NAS score 2.761.6 3.261.8 2.461.3 0.105
Steatosis grade 1.860.8 1.960.8 1.760.7 0.309
1 (n) 21 8 13
2 (n) 18 7 11
3( n ) 1 3 7 5
Hepatocelular ballooning (n) 3 2 1 0.379
Lobular inflammatory grade 0.860.8 1.160.9 0.660.8 0.084
0 (n) 23 7 16
1( n ) 1 6 8 8
2( n ) 1 1 6 5
3( n ) 1 1 0
Fibrosis stage 1.460.8 2.160.5 0.960.3 ,0.001
0( n ) 4 0 4
1 (n) 25 0 25
2 (n) 20 20 0
3( n ) 1 1 0
4( n ) 1 1 0
NASH=non alcoholic steatohepatitis, BMI=body mass index, WTH=waist to hip, AST=aspartate aminotransferase, ALT=alanine aminotransferase, c-GT=c-glutamyl
transpeptidase, ALP=alkaline phosphatase, NAS=NAFLD activity score.
P*=significance level in the comparison between NASH and non NASH.
doi:10.1371/journal.pone.0031738.t001
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and normal lean controls
Deltoid muscle morphology was evaluated in 34 lean healthy
controls and 51 morbidly obese patients with NAFLD.
There were no differences in number, proportion, length and
length variability of type 1 and 2 fibers in controls and NAFLD
patients, as well as NASH and non-NASH obese patients.
However, severity of hepatic steatosis was associated with
progressively higher type 1 (p=0.021) and type 2 (p=0.007) fiber
length. No associations with fibrosis stage or lobular inflammatory
grade were found.
The presence of EMCL and IMCL (Figure 3B and 3A
respectively) was more frequent in obese NAFLD patients as
compared to controls (70.6% vs 8.8%, p,0.001 and 31.4% vs 0%,
p,0.001, respectively). Also, although the percentage of patients
presenting EMCL was not different between NASH and non-
NASH obese patients, the percentage of patients with IMCL was
significantly higher in NASH patients (59.1 vs 10.3, p,0.001; OR
12.52 [2.89–54.26], p,0.001). Furthermore, even though there
was no significant association between IMCL and steatosis
severity, there was a significant tendency to a progressive increase
in the prevalence of IMCL and the severity of fibrosis stage
(p=0.010) and lobular inflammation grade (p=0.029). In turn, no
association was found between EMCL and liver histology
(Figure 4). Surprisingly, IMCL or EMCL were not associated
with metabolic factors, namely BMI, waist to hip ratio, insulin
resistance or HOMA-IR, hypertension, diabetes mellitus, dyslipi-
demia or the metabolic syndrome. Furthermore, IMCL or EMCL
did not change in patients under treatment with anti-diabetics or
statins, nor with cytokines levels, namely adiponectin, leptin or
ghrelin.
In morbidly obese patients, as well as in controls, there was no
significant muscle inflammation or necrosis, irrespective of the
presence of IMCL. Lean controls presented more mitochondrial
aggregates, and less cytochrome c oxidase negative myocytes and
glycogen overload. However, no significant differences were
observed between NASH and non-NASH obese patients
(Table 2). Still, there was a tendency, though with no statistical
significance, to a higher percentage of glycogen overload
prevalence with increasing steatosis (29% vs 39% vs 59%,
p=0.101). Also, the prevalence of cytochrome c oxidase negative
fibers increased gradually with lobular inflammation activity
severity (p=0.045). No other associations, namely with steatosis,
fibrosis or lobular inflammation severity were found.
Muscle mitochondrial enzymes activity in morbidly obese
NAFLD patients and normal lean controls
Muscle mitochondrial activity of citrate synthase and respiratory
chain complex I, II, III and IV were evaluated in 25 lean healthy
controls and 42 morbidly obese patients with NAFLD.
In obese patients, there was a lower citrate synthase activity
compared with lean controls, translating into a decreased
mitochondrial content (101630 vs 117634 nmol/min/mg/
PNC, p=0.047). Moreover, complex I and III activities were
higher in obese NAFLD patients compared with controls (20610
vs 1665 nmol/min/mg/PNC and 87646 vs 68636 nmol/min/
mg/PNC, p,0.05 respectively). There were no differences in
enzymatic activities between obese groups (Table 3).
There were also no differences in enzymatic activities regarding
the presence of IMCL. On the contrary, the presence of EMCL
was globally associated with lower citrate synthase (99616 vs
115632 nmol/min/mg/PNC, p=0.047) and complex II (1566
vs 1865 nmol/min/mg/PNC, p=0.026) activities, and higher
complex III activities (91650 vs 69631 nmol/min/mg/PNC,
p=0.043). However, differences were lost when analyzing obese
patients with NAFLD alone.
In addition, in patients with insulin resistance, complex I activity
was higher (24611 vs 16618 nmol/min/mg/PNC, p=0.023)
whereas complex IV (1564 vs 2169 nmol/min/mg/PNC,
p=0.036) was lower. Also, complex I activity positively correlated
with glucose (r=0.38, p=0.029) and insulin (r=0.40, p=0.018)
plasma levels, although there were no differences regarding the
presence of diabetes mellitus or metabolic syndrome. Surprisingly,
adiponectin and complex III activity presented a negative
correlation (r=20.41, p=0.014).
Concerning liver lesion, complex III activity was positively
correlated with ALT levels (r=0.35, p=0.024) whereas complex
IV negatively correlated with AST (r=20.41, p=0.008) and ALT
(r=20.33, p=0.031) levels. Complex I activity gradually
increased with progressive steatosis (p=0.049) and fibrosis severity
Figure 3. Deltoid muscle histology. Slides showing intramyocellular fat accumulation highlighted in Oil red, (406) (A) and inter fascicular fat,
stained with hematoxylin & eosin (106) (B).
doi:10.1371/journal.pone.0031738.g003
Figure 2. Insulin resistance according to liver histology. Differences in HOMA-IR according to the severity of steatosis (A), fibrosis stage (B) and
lobular inflammatory grade (C). Error bars: 95% CI (not possible to calculate for fibrosis stage 3 or 4 or lobular inflammation grade 3, only one patient).
HOMA-IR progressively increased with severity of hepatic steatosis, lobular inflammation and fibrosis.
doi:10.1371/journal.pone.0031738.g002
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activities and steatosis, fibrosis or lobular inflammation severity
(Figures 5, 6 and 7).
Muscle insulin signaling cascade in morbidly obese
NAFLD patients and its relation with muscle and hepatic
morphology
The insulin signaling cascade in the muscle was evaluated in 26
morbid obese patients with NAFLD, of whom 43% had NASH,
59% insulin resistance and 26% type 2 diabetes mellitus. No
differences were found between insulin cascade proteins and the
presence of insulin resistance assessed by HOMA-IR, diabetes
mellitus or the metabolic syndrome. However, there was a trend to
a positive correlation between glucose plasma levels and
phosphorylated IRS-1 (r=0.480, p=0.0913) and a negative
correlation with HDL-cholesterol plasma levels (r=20.393,
p=0.057). Regarding BMI, there was a positive correlation with
increased phosphorylated IRS-1 (r=0.388, p=0.043) and a trend
Figure 4. Distribution of muscle fat according to liver histology. Prevalence of IMCL and EMCL according to steatosis severity (A and B),
fibrosis stage (C and D) and lobular inflammation grade (E and F). Error bars: 95% CI. IMCL was progressively more prevalent with more severe liver
disease, namely fibrosis and lobular inflammation. EMCL did not associate with hepatic histology.
doi:10.1371/journal.pone.0031738.g004
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p=0.093). Surprisingly, no correlations were found with adipo-
nectin. However, phosphorylated IRS-1 was positively correlated
with leptin (r=0.393, p=0.047), while the insulin receptor protein
levels were positively correlated with ghrelin levels (r=0.447,
p=0.042).
Although there were no differences regarding the presence of
EMCL and the insulin cascade, IMCL was associated with a 1.5
fold decrease in phosphorylated Akt levels (p=0.059). The only
correlations found with respiratory chain enzymes activities were a
positive correlation between complex I and phosphorylated insulin
receptor (r=0.537, p=0.007) and a trend to a negative
correlation between complex III and phosphorylated Akt levels
(r=20.378, p=0.069).
Concerning hepatic histology, patients with at least moderate
steatosis presented a 2.4-fold increase in phosphorylated insulin
receptor (p=0.005), a trend to a 1.4-fold increase in phosphor-
ylated IRS-1 (p=0.052), a 2.7-fold increase in total Akt
(p=0.015), and a 2.4-fold decrease in phosphorylated Akt levels
(p=0.004). In addition, there was a gradual increase of
phosphorylated insulin receptor (p=0.014) and a gradual decrease
of phosphorylated Akt (p,0.001), with increased steatosis severity
(Figure 8). Similarly, the presence of at least moderate lobular
inflammation associated with a 2.1-fold decrease in total Akt
(p=0.043) and a 1.9-fold decrease in phosphorylated Akt
(p=0.005). Finally, lobular inflammation severity was associated
with progressive decrease in phosphorylated Akt (p=0.013), while
the presence of fibrosis was only associated with a 2-fold increase
in phosphorylated insulin receptor levels (p=0.008).
Discussion
To our knowledge, this is the first study that evaluates the
interplay between muscle and hepatic histology in morbid obese
patients. As expected, morbid obese patients presented a higher
prevalence of fatty muscle than lean controls. However, unlike the
liver, in which ectopic fat may be associated with necroinflamma-
tion and fibrosis progression our results suggest that ectopic fat in
Table 2. Muscle morphology in morbidly obese patients with NAFLD and lean controls.
Feature Controls (N=35) Obese (N=51) P* NASH (N=22) Non-NASH (N=29) P**
T1F (N) 200637 215638 0.102 215637 214640 0.894
T1F proportion (%) 50695 4 610 0.102 54695 3 610 0.894
T1F length (mm) 52.568.3 55.6610.0 0.154 55.168.6 55.9611.1 0.792
T1F D coefficient 172.1627.7 182.4620.8 0.069 185.7620.9 179.9620.8 0.378
T2F (N) 202644 185638 0.076 184637 186640 0.894
T2F proportion (%) 50611 46610 0.076 46694 7 610 0.894
T2F length (mm) 52.5610.2 52.8611.6 0.911 52.068.5 53.3613.7 0.708
T2F D coefficient 219.96103.1 215.3631.0 0.783 217.4635.1 213.6628.3 0.698
EMCL (%) 8.8 70.6 ,0.001 72.7 69.0 0.510
IMCL (%) 0 31.4 ,0.001 59.1 10.3 ,0.001
RRF (%) 8.8 21.6 0.103 18.2 24.1 0.437
Mitochondrial aggregates 79.4 51 0.007 45.5 55.5 0.689
COX (%) 5.9 39.2 ,0.001 45.5 34.5 0.306
Inflammation 0 2.0 0.600 0 3.4 0.569
Necrosis 2.9 7.8 0.331 9.1 6.9 0.814
Glycogen overload 0 39.2 ,0.001 40.9 37.9 0.528
NASH=non alcoholic steatohepatitis, T1F=type 1 fibers, D coefficient=variability coefficient, T2F=type 2 fibers, EMCL=extramyocellular lipids,
EMCL=intramyocellular lipids, RRF=ragged red fibers presence, COX=presence of cytochrome oxidase negative fibers.
P*=significance level in the comparison between controls and obese patients;
P**=significance level in the comparison between NASH and non NASH.
doi:10.1371/journal.pone.0031738.t002
Table 3. Muscle mitochondrial respiratory chain enzymes activity in morbidly obese patients with NAFLD and lean controls.
Feature Controls (N=25) Obese (N=42) P* NASH (N=18) Non-NASH (N=24) P**
Citrate Synthase 117.3634.0 101.3629.7 0.047 109.2632.7 95.3626.5 0.138
Complex I 16.265.3 20.3610.5 0.040 22.6612.1 18.669.0 0.223
Complex II 17.063.8 15.666.3 0.242 16.665.4 14.866.9 0.364
Complex III 67.7635.7 87.4646.3 0.036 83.0643.7 90.6648.8 0.604
Complex IV 18.265.3 17.767.7 0.755 17.267.0 18.068.4 0.738
NASH=non alcoholic steatohepatitis. All enzymatic activities expressed in nmol/min/mg PNC.
P*=significance level in the comparison between controls and obese patients;
P**=significance level in the comparison between NASH and non NASH.
doi:10.1371/journal.pone.0031738.t003
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fact, no evidence of muscle inflammation or cellular necrosis was
found in histology assessment. Previous studies had shown an
association between IMCL and hepatic steatosis [7,18]. In the
present study, we further demonstrated that IMCL associates with
a more than 12-fold risk for NASH in morbid obese patients, as
well as with hepatic inflammation and advanced fibrosis. Indeed,
IMCL may translate into a higher susceptibility to lipotoxicity and
a decreased ability to keep lipids in inert reservoirs. It would be
interesting to understand if there is a temporal sequence between
IMCL and NASH development with one favoring the other or if
both are parallel phenomena that share the same risk factors. For
Figure 5. Muscle mitochondrial enzymatic activities according to hepatic steatosis degree. Differences in mean mitochondrial enzymatic
activities, citrate synthase (A), complex I (B), complex II (C), complex III (D) and complex IV (E) with steatosis severity. Error bars: 95% CI. ComplexI
activity progressively increased with hepatic steatosis severity.
doi:10.1371/journal.pone.0031738.g005
Figure 6. Muscle mitochondrial enzymatic activities according to hepatic fibrosis severity. Differences in mean mitochondrial enzymatic
activities, citrate synthase (A), complex I (B), complex II (C), complex III (D) and complex IV (E) with fibrosis severity. Error bars: 95% CI. There wasa
trend to a progressive increase in complex I activity according to fibrosis stage.
doi:10.1371/journal.pone.0031738.g006
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possible to study in animal models. Although IMCL was not
associated with increased HOMA-IR or overt diabetes mellitus, it
was associated with impairment in muscle insulin signaling
cascade. Therefore, IMCL may constitute a more sensitive and
earlier marker of glucose metabolism disturbance. Finally, IMCL
did not associate with muscle mitochondrial dysfunction, thus
suggesting ectopic fat accumulation to be a result of an excess of
fatty acids supply rather than an impairment in mitochondrial
fatty acids oxidation [29].
Our findings also show a decrease in muscle mitochondrial
content, as assessed by citrate synthase activity in obese patients as
compared to controls. However, we did not find any signs of
mitochondrial dysfunction. On the opposite, obese patients
presented increased complex I and III activities. Previous studies
had shown that mitochondrial content and fatty acids oxidation
are decreased in obesity [30,31]. This may be explained by lipid-
derived oxidative mitochondrial damage [32,33]. Alternatively,
mitochondrial content may decrease as a result of sedentary
lifestyle rather than obesity itself [34,35,36,37]. However, it has
also been previously described that isolated mitochondria from
obese subjects maintain its ability to oxidize fatty acids [32]. There
may be, indeed, a compensatory increase in mitochondrial
enzymes activity in response to fat overload [38]. In fact, both
obesity and high fat diets are associated with increased protein
expression of transcriptional coactivator peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1a) [39], the
main transcription factor regulating mitochondrial biogenesis and
oxidative phosphorylation enzymes expression [40]. However, we
found no associations between IMCL and mitochondrial enzymes
activity. In this group of obese patients, insulin resistance appears
to be associated with higher complex I activity, which is not the
case with diabetes mellitus. Also, insulin resistance negatively
correlated with complex IV activity. Mitochondrial dysfunction
may not be a cause, but rather a consequence of insulin resistance.
In accordance, in a chronological model of diet induced obesity in
rats, mitochondrial oxidative capacity first presented a compen-
satory increase, whereas mitochondrial dysfunction was a late
event, only appearing after changes in lipid metabolism and
insulin sensitivity had occurred [41]. Regarding hepatic lesion,
steatosis and fibrosis severity were progressively associated with
higher complex I activity, which may suggest a muscle
compensatory mechanism to a higher fat overload. Although
NASH was not associated with mitochondrial enzymes activity
changes, aminotransferases levels were correlated negatively with
complex IV activity, which may be translated into a higher hepatic
necroinflammatory activity in patients with sustained metabolic
disturbance.
Regarding the insulin signaling cascade, activation of the first
steps, namely insulin receptor and IRS-1, correlated with BMI,
glucose levels and plasma lipids disturbance. However, in the
following step, Akt phosphorylation rather presented a negative
correlation with the above mentioned metabolic factors. Similar
correlations were found, regarding leptin and ghrelin levels,
mitochondrial enzymes activities (complex I and III), IMCL
accumulation, and degree of hepatic steatosis, inflammation and
fibrosis. These data suggest a more intense metabolic disturbance,
with compensatory hyperinsulinism and insulin receptor stimu-
lation in the muscle during NAFLD progression in obese patients.
Also, in this set, insulin resistance in muscle seems to occur
distally in insulin signaling cascade. This is corroborated by the
data of Cusi et al. that described muscle resistance in the
phosphoinositide-3-kinase (Pi3K)/Akt signaling pathway, with an
intact stimulation of mitogen-activated protein kinase (MAPK)
translating into normal insulin receptor function in obese
individuals [42]. In fact, skeletal muscle ceramide content, which
is increased in obese patients [43], is known to inhibit insulin
signaling via inhibition at Akt levels [44]. Strong evidence
suggests that muscle accumulation of diacylglycerol and long
chain acyl-CoA leads to insulin resistance through the activation
Figure 7. Muscle mitochondrial enzymatic activities according to hepatic inflammation severity. Differences in mean mitochondrial
enzymatic activities, citrate synthase (A), complex I (B), complex II (C), complex III (D) and complex IV (E) with lobular inflammation severity. Error bars:
95% CI. There was a trend to a progressive increase in complex III activity according to lobular inflammation grade.
doi:10.1371/journal.pone.0031738.g007
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IRS-1 tyrosine phosphorylation [45,46]. In fact, muscle diacyl-
glycerol accumulation seems to be more related with an increased
supply of fatty acids in the diet, while ceramide accumulation is
associated with physical inactivity [47]. Interestingly, physical
inactivity may be a major factor contributing to the development
of insulin resistance in morbid obesity, where an increase in
diacylglycerol content may not occur [43]. However, previous
studies from our group [48] showed a decrease in insulin receptor
and IRS-1 tyrosine phosphorylation in morbid obese patients
with severe NASH, which suggests that at some point in the
progression of NAFLD, a continuous overstimulation of insulin
receptor may lead to impairment in insulin signaling more
proximally in the cascade.
Figure 8. Muscle insulin receptor pathway according to hepatic histology. Changes in phosphorylated insulin receptor and Akt in muscle
tissue with hepatic steatosis severity (A). Insulin receptor phosphorylation in the muscle increases with hepatic steatosis severity (B) and Akt
phosphorylation decreases with steatosis (C). Changes in phosphorylated Akt in muscle tissue with hepatic lobular inflammation grade (D). Akt
phosphorylation in the muscle decreases with lobular inflammation grade (E). Total proteins were extracted for immunoblot analysis as described.
Representative immunoblots for insulin receptor, phosphorylated insulin recptor, Akt, and phosphorylated Akt are shown. Tissue blots of
phosphorylated proteins were normalized to corresponding unphosphorylated proteins. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as loading control. Error bars: 95% CI.
doi:10.1371/journal.pone.0031738.g008
The Muscle in Nonalcoholic Fatty Liver Disease
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in insulin pathway signaling could be tumor necrosis factor-alpha
(TNF-a). Recently, it has been shown that local generation of
TNF-a in skeletal muscle acts paracrinally or autocrinally,
inducing insulin resistance [49]. Locally produced pro-TNF-a is
a membrane-bound protein that is then processed and released
from the cell surface by the action of TNF-a converting enzyme
(TACE). Tissue inhibitor of matrix metalloproteinase 3 (TIMP3) is
TACE’s natural inhibitor [49]. In vitro studies, as well as in vivo,i n
mice and humans, had shown that fatty acids and high fat diet
inhibits TIMP3 expression leading to an increase in TACE
activity, in the muscle and in the liver [49,50]. In the muscle,
TACE/TIMP3 deregulation associates with insulin resistance
[49], and in the liver with NASH development [50,51].
One unexpected finding was the lack of association between
adiponectin levels and presence of NASH or lipid accumulation in
the liver. It is produced mainly by adipocytes, however it is
inversely proportional to the adipose mass and visceral obesity,
most likely through a negative loop from down-regulation by
tumor necrosis factor-a (TNF-a) derived from adipose tissue
infiltrating macrophages. Adiponectin has favorable metabolic
effects, acting as an insulin sensitizer as well as an anti-
inflammatory and TNF-a antagonist [52]. It is known to decrease
hepatic fat content in animal models [53] and it is believed to
inversely relate with NAFLD in human; however, not all studies
are consensual and a meta-analysis using liver biopsy data failed to
demonstrate it [54]. Also, differences in adiponectin levels between
patients with simple steatosis and NASH are still not clear [55].
The failure to show an association between adiponectin and
hepatic or muscle histology, as well as with deregulation in insulin
signaling may be due to lack of power to detect them. However,
we can speculate that in a population of morbid obese patients,
where adiponectin levels are already extremely low and associated
with NAFLD, the correlation with more severe disease such as
NASH is weakened.
Our study has some limitations, mainly in respect to the normal
control group. When evaluating muscle morphology and muscle
mitochondrial function, anthropometric, laboratorial and liver
biopsy data were not collected. Also, when assessing muscle insulin
cascade signaling, a comparison with a healthy lean control group
was not possible. However, the main goal of the study was to assess
the muscle morphology and metabolism according to liver injury
in a homogenous group of patients, with similar metabolic risk
factors, namely BMI.
In conclusion, obesity is associated with IMCL in a similar and
parallel fashion with NAFLD. However, in opposite to the liver in
which ectopic fat seems to be associated with a risk of liver disease
progression with necroinflammatory and fibrogenic responses, in
the muscle, ectopic fat does not lead to inflammation or myocyte
necrosis. Moreover, IMCL is associated with a higher risk of
NASH and advanced fibrosis. Also, muscle mitochondrial
dysfunction does not appear to be a major driving mechanism
to IMCL accumulation, insulin resistance and liver disease in
obese patients. Skeletal muscle insulin resistance occurs at a late
point in the insulin signaling cascade and is associated with IMCL
and NAFLD severity.
Author Contributions
Conceived and designed the experiments: MVM HCP TE CR. Performed
the experiments: MVM DF RC ARS TE JC FC AC CR HCP. Analyzed
the data: MVM HCP. Contributed reagents/materials/analysis tools:
MVM DF RC ARS TE JC FC AC CR HCP. Wrote the paper: MVM
HCP DF RC CR.
References
1. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH (2009) Systematic review
of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol
51: 371–379.
2. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology 44: 865–873.
3. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous
octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:
773–795.
4. Kuhlmann J, Neumann-Haefelin C, Belz U, Kalisch J, Juretschke HP, et al.
(2003) Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-
spectroscopic study in Zucker diabetic fatty rats. Diabetes 52: 138–144.
5. van Herpen NA, Schrauwen-Hinderling VB (2008) Lipid accumulation in non-
adipose tissue and lipotoxicity. Physiol Behav 94: 231–241.
6. Goodpaster BH, Theriault R, Watkins SC, Kelley DE (2000) Intramuscular lipid
content is increased in obesity and decreased by weight loss. Metabolism 49:
467–472.
7. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, et al. (2002) Assessment
of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance
spectroscopy in lean and obese adolescents: relationships to insulin sensitivity,
total body fat, and central adiposity. Diabetes 51: 1022–1027.
8. Thamer C, Machann J, Bachmann O, Haap M, Dahl D, et al. (2003)
Intramyocellular lipids: anthropometric determinants and relationships with
maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab 88:
1785–1791.
9. Bachmann OP, Dahl DB, Brechtel K, Machann J, Haap M, et al. (2001) Effects
of intravenous and dietary lipid challenge on intramyocellular lipid content and
the relation with insulin sensitivity in humans. Diabetes 50: 2579–2584.
10. Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, et al.
(2003) Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol
Metab 284: E741–747.
11. Hajduch E, Balendran A, Batty IH, Litherland GJ, Blair AS, et al. (2001)
Ceramide impairs the insulin-dependent membrane recruitment of protein
kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells.
Diabetologia 44: 173–183.
12. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, et al. (2000) Long-
chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in
rat and human muscle. Am J Physiol Endocrinol Metab 279: E554–560.
13. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, et al. (2007) Lipid
mediators of insulin resistance. Nutr Rev 65: S39–46.
14. Eckardt K, Taube A, Eckel J (2011) Obesity-associated insulin resistance in
skeletal muscle: Role of lipid accumulation and physical inactivity. Rev Endocr
Metab Disord 12: 163–172.
15. Dengel DR, Pratley RE, Hagberg JM, Rogus EM, Goldberg AP (1996) Distinct
effects of aerobic exercise training and weight loss on glucose homeostasis in
obese sedentary men. J Appl Physiol 81: 318–325.
16. Perseghin G, Scifo P, Danna M, Battezzati A, Benedini S, et al. (2002) Normal
insulin sensitivity and IMCL content in overweight humans are associated with
higher fasting lipid oxidation. Am J Physiol Endocrinol Metab 283: E556–564.
17. Liu L, Zhang Y, Chen N, Shi X, Tsang B, et al. (2007) Upregulation of
myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and
protects against fat-induced insulin resistance. J Clin Invest 117: 1679–1689.
18. Kitajima Y, Eguchi Y, Ishibashi E, Nakashita S, Aoki S, et al. (2010) Age-related
fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver
disease. J Gastroenterol 45: 218–224.
19. (1992) Gastrointestinal surgery for severe obesity: National Institutes of Health
Consensus Development Conference Statement. Am J Clin Nutr 55:
615S–619S.
20. Group NHBPEPW (1993) Report on primary prevention of hypertension. Arch
Intern Med 153: 325–334.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
22. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatol-
ogy 37: 917–923.
23. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, et al. (2003) Follow-up
report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160–3167.
The Muscle in Nonalcoholic Fatty Liver Disease
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e3173824. (2002) Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation
106: 3143–3421.
25. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G (2010) A position
statement on NAFLD/NASH based on the EASL 2009 special conference.
J Hepatol 53: 372–384.
26. Younossi Z, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, et al. (2011)
Pathologic criteria for non-alcoholic steatohepatitis (NASH): Inter-protocol
agreement and ability to predict liver-related mortality. Hepatology 53:
1874–1882.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver
disease. Hepatology 41: 1313–1321.
28. Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, et al. (2006)
Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis.
Eur J Gastroenterol Hepatol 18: 21–29.
29. Kraegen EW, Cooney GJ, Turner N (2008) Muscle insulin resistance: a case of
fat overconsumption, not mitochondrial dysfunction. Proc Natl Acad Sci U S A
105: 7627–7628.
30. Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA (2000) Lipid
oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol
Metab 279: E1039–1044.
31. Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:
2944–2950.
32. Holloway GP, Bonen A, Spriet LL (2009) Regulation of skeletal muscle
mitochondrial fatty acid metabolism in lean and obese individuals. Am J Clin
Nutr 89: 455S–462S.
33. Abdul-Ghani MA, DeFronzo RA (2010) Pathogenesis of insulin resistance in
skeletal muscle. J Biomed Biotechnol 2010: 476279.
34. Hawley JA, Lessard SJ (2007) Mitochondrial function: use it or lose it.
Diabetologia 50: 699–702.
35. Alves RM, Vitorino R, Figueiredo P, Duarte JA, Ferreira R, et al. (2010)
Lifelong physical activity modulation of the skeletal muscle mitochondrial
proteome in mice. J Gerontol A Biol Sci Med Sci 65: 832–842.
36. Safdar A, Hamadeh MJ, Kaczor JJ, Raha S, Debeer J, et al. (2010) Aberrant
mitochondrial homeostasis in the skeletal muscle of sedentary older adults. PLoS
One 5: e10778.
37. Rimbert V, Boirie Y, Bedu M, Hocquette JF, Ritz P, et al. (2004) Muscle fat
oxidative capacity is not impaired by age but by physical inactivity: association
with insulin sensitivity. Faseb J 18: 737–739.
38. Turner N, Bruce CR, Beale SM, Hoehn KL, So T, et al. (2007) Excess lipid
availability increases mitochondrial fatty acid oxidative capacity in muscle:
evidence against a role for reduced fatty acid oxidation in lipid-induced insulin
resistance in rodents. Diabetes 56: 2085–2092.
39. Hancock CR, Han DH, Chen M, Terada S, Yasuda T, et al. (2008) High-fat
diets cause insulin resistance despite an increase in muscle mitochondria. Proc
Natl Acad Sci U S A 105: 7815–7820.
40. Benton CR, Wright DC, Bonen A (2008) PGC-1alpha-mediated regulation of
gene expression and metabolism: implications for nutrition and exercise
prescriptions. Appl Physiol Nutr Metab 33: 843–862.
41. Chanseaume E, Tardy AL, Salles J, Giraudet C, Rousset P, et al. (2007)
Chronological approach of diet-induced alterations in muscle mitochondrial
functions in rats. Obesity (Silver Spring) 15: 50–59.
42. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, et al. (2000) Insulin
resistance differentially affects the PI 3-kinase- and MAP kinase-mediated
signaling in human muscle. J Clin Invest 105: 311–320.
43. Thrush AB, Brindley DN, Chabowski A, Heigenhauser GJ, Dyck DJ (2009)
Skeletal muscle lipogenic protein expression is not different between lean and
obese individuals: a potential factor in ceramide accumulation. J Clin Endocrinol
Metab 94: 5053–5061.
44. Adams JM, 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, et al.
(2004) Ceramide content is increased in skeletal muscle from obese insulin-
resistant humans. Diabetes 53: 25–31.
45. Yu C, Chen Y, Cline GW, Zhang D, Zong H, et al. (2002) Mechanism by which
fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-
associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:
50230–50236.
46. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance:
unravelling the mechanism. Lancet 375: 2267–2277.
47. Dube JJ, Amati F, Toledo FG, Stefanovic-Racic M, Rossi A, et al. (2011) Effects
of weight loss and exercise on insulin resistance, and intramyocellular
triacylglycerol, diacylglycerol and ceramide. Diabetologia 54: 1147–1156.
48. Ferreira DM, Castro RE, Machado MV, Evangelista T, Silvestre A, et al. (2011)
Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese
patients is associated with different stages of non-alcoholic fatty liver disease.
Diabetologia 54: 1788–1798.
49. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, et al. (2009)
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of
metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic
patients: a new mechanism of insulin resistance in humans. Diabetologia 52:
2169–2181.
50. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, et al. (2010)
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin
resistance and hepatosteatosis in mice. Hepatology 51: 103–110.
51. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, et al. (2009)
Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and
adipose tissue inflammation in mice. Gastroenterology 136: 663–672 e664.
52. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E (2010) The role of adiponectin in
the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes
Obes Metab 12: 365–383.
53. Xu A, Wang Y, Keshal H, Xu LY, Lam KS, et al. (2003) The fat-derived
hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in
mice. J Clin Invest 112: 91–100.
54. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J (2011) Serum total
adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-
analysis. Metabolism 60: 313–326.
55. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, et al. (2005) Plasma
adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and
hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:
3498–3504.
The Muscle in Nonalcoholic Fatty Liver Disease
PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e31738